Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytosorbents Corp CTSO

Healthcare Medical Devices
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive... see more

Recent & Breaking News (NDAQ:CTSO)

CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank

PR Newswire July 5, 2017

CytoSorbents Announces Director and Management Open Market Stock Purchases

PR Newswire June 15, 2017

CytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors

PR Newswire June 6, 2017

Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer

PR Newswire May 30, 2017

CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference

PR Newswire May 24, 2017

Aferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021

PR Newswire May 22, 2017

CytoSorbents Reports First Quarter 2017 Financial Results

PR Newswire May 8, 2017

Investor Network: CytoSorbents Corporation to Host Earnings Call

Accesswire May 8, 2017

CytoSorbents Announces Positive REFRESH I Trial Results

PR Newswire May 5, 2017

CytoSorbents to Report Q1 2017 Operating and Financial Results

PR Newswire May 2, 2017

CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification

PR Newswire April 24, 2017

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  March 31, 2017

CytoSorbents Announces Pricing of Follow-On Offering

PR Newswire March 31, 2017

CytoSorbents Announces Proposed Offering of Common Stock

PR Newswire March 30, 2017

CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia

PR Newswire March 28, 2017

CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference

PR Newswire March 27, 2017

Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board

PR Newswire March 22, 2017

CytoSorb® Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy

PR Newswire March 20, 2017

CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy's Laboratories

PR Newswire March 16, 2017

CytoSorbents Highlights Activities at the 22nd International Conference on Advances in Critical Care Nephrology

PR Newswire March 7, 2017